<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00731900</url>
  </required_header>
  <id_info>
    <org_study_id>9561707009</org_study_id>
    <nct_id>NCT00731900</nct_id>
  </id_info>
  <brief_title>Pharmacogenetic Study for Topiramate-Induced Cognitive Dysfunction</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <brief_summary>
    <textblock>
      Topiramate (TPM) is an antiepileptic drug with a unique mode of action that is often useful&#xD;
      in patients refractory to other drugs. However its use is restricted by the high incidence of&#xD;
      cognitive adverse drug reactions (ADRs) that are associated with TPM exposure. TPM has been&#xD;
      shown to cause particular cognitive ADRs, characterized by verbal fluency, attention, working&#xD;
      memory and language deficits, at a much higher rate than other antiepileptic drugs. There do&#xD;
      not appear to be obvious differences between patients that do or do not experience cognitive&#xD;
      ADRs when on TPM (e.g. age, sex, concomitant medications, diagnosis), which suggests a&#xD;
      genetic contributor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cognitive Dysfunction</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients with epilepsy or patients with migraine treated by topiramate&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult (&gt;17 years old) patients with epilepsy or patients with migraine treated by&#xD;
             topiramate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergy to topiramate&#xD;
&#xD;
          -  abnormal liver or renal function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horng-Huei Liou, MD;PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Horng-Huei Liou, MD;PhD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>8325</phone_ext>
    <email>hhl@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Horng-Huei Liou, MD;PhD</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>8325</phone_ext>
      <email>hhl@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>August 7, 2008</study_first_submitted>
  <study_first_submitted_qc>August 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2008</study_first_posted>
  <last_update_submitted>August 8, 2008</last_update_submitted>
  <last_update_submitted_qc>August 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Hrong-Huei Liou, MD;PhD</name_title>
    <organization>National Taiwan University Hospital</organization>
  </responsible_party>
  <keyword>pharmacogenetic</keyword>
  <keyword>study</keyword>
  <keyword>Topirmate</keyword>
  <keyword>induced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

